Genentech announced that its Phase 3 study of Avastin (bevacizumab) plus chemotherapy following surgery in patients with early-stage colon cancer did not meet its primary endpoint of improvement in disease-free survival. The study, also known as NSABP C-08, is a randomized multi-center study designed to evaluate the effect of FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) chemotherapy with or without Avastin on disease-free survival in patients with resected Stage II or III adenocarcinoma of the colon. The secondary endpoint of the study was overall survival.
Avastin, an angiogenesis inhibitor, is already indicated for the treatment of: metastatic colorectal carcinoma, in combination with 5-FU-based chemotherapy; first-line treatment of unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel and metastatic HER2-negative breast cancer in patients who have not received chemotherapy, in combination with paclitaxel.
For more information call (800) 821-8590 or visit www.avastin.com.